KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 20925 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study. PMID 41818638 · J Clin Oncol · 2026-Apr-20 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer. PMID 41802242 · J Clin Oncol · 2026-Apr-20 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 2 Figure · 4 Panel · risk unclear
Nivolumab ± Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II Trial. PMID 41774886 · J Clin Oncol · 2026-Apr-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update. PMID 41747202 · J Clin Oncol · 2026-Apr-20 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Ultra-Low-Dose Immunotherapy in Relapsed Refractory Solid Tumors: Phase III Superiority Randomized Trial (DELII). PMID 41604598 · J Clin Oncol · 2026-Apr-20 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Relative efficacy, safety, and immunogenicity analysis of two doses versus one dose of recombinant coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomized, double blinded phase 3 trial. PMID 41863180 · Vaccine · 2026-Apr-19 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Immunogenicity and safety of higher-dose cell-based adjuvanted quadrivalent influenza vaccines: Combined results of randomised, controlled dose-finding and dose-confirmation studies. PMID 41855648 · Vaccine · 2026-Apr-19 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study. PMID 41974150 · Lancet · 2026-Apr-18 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial. PMID 41974149 · Lancet · 2026-Apr-18 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Long-Term Outcomes, Moderators, and Predictors in Online Mindfulness-Based Cognitive Therapy for People With Cancer: Secondary Analysis of a Randomized Controlled Trial. PMID 41996463 · J Med Internet Res · 2026-Apr-17 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Effect of Probiotics on the Clinical Outcome and Inflammatory Response in Gastric Cancer Surgery: A Double Blinded Randomized Control Trial. PMID 41996041 · J Gastrointest Cancer · 2026-Apr-17 Study is a randomized trial in gastric cancer but is excluded because it does not involve a drug-containing intervention (probiotics are not a drug) and its primary endpoints are postoperative recovery metrics, not oncology time-to-event efficacy outcomes like OS or PFS. Phase is not stated.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Intravenous Thrombolysis at Primary Stroke Centers Versus Comprehensive Stroke Centers: Analysis From the AcT Trial. PMID 41992950 · Can J Neurol Sci · 2026-Apr-17 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
FDG-PET/CT based small volume accelerated immuno chemoradiotherapy in locally advanced NSCLC (PACCELIO) - a randomized, open-label, multicenter phase II trial protocol. PMID 41992146 · BMC Cancer · 2026-Apr-17 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Oral selective estrogen receptor degraders in hormone receptor-positive, HER2-negative advanced breast cancer: a systematic review and meta-analysis. PMID 41991764 · Breast Cancer Res Treat · 2026-Apr-17 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Randomized, double-blind treatment withdrawal or continuation with ruxolitinib cream in vitiligo: findings from the Topical Ruxolitinib Evaluation in Vitiligo (TRuE-V) long-term extension phase III study. PMID 41453117 · Br J Dermatol · 2026-Apr-17 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Experiences of Migraine and Erenumab Treatment in Japan: Qualitative Interviews with Clinical Trial Participants. PMID 41991782 · Patient · 2026-Apr-16 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Randomized Trial of Adjunctive Prednisolone for Kawasaki Disease. PMID 41985133 · N Engl J Med · 2026-Apr-16 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Asundexian for Secondary Stroke Prevention. PMID 41985132 · N Engl J Med · 2026-Apr-16 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Ianalumab plus Eltrombopag in Immune Thrombocytopenia. PMID 41363800 · N Engl J Med · 2026-Apr-16 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Phase 2 trial of exercise and low-dose ibuprofen for cancer-related cognitive impairment in patients receiving chemotherapy. PMID 42003280 · Cancer · 2026-Apr-15 The study is a Phase 2 randomized trial in oncology patients with a drug intervention, but it does not meet the definitive phase requirement (Phase III/IIIb or Phase II/III) and does not report a time-to-event efficacy endpoint, which are required for inclusion.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Belantamab mafodotin, bortezomib, and dexamethasone for RRMM in the Japan expansion cohort of the phase 3 DREAMM-7 trial. PMID 41986580 · Int J Hematol · 2026-Apr-15 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Demethylation-primed tandem CD19/CD20 CAR T cells in relapsed/refractory B-cell lymphoma: a phase I/II trial. PMID 41986386 · Nat Commun · 2026-Apr-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Protocol of a randomised controlled trial: comparing the safety and efficacy of two methadone conversion strategies in Chinese patients with cancer pain receiving high-dose opioids. PMID 41985948 · BMJ Open · 2026-Apr-15 This is a clinical trial protocol (not a results report) for a randomized trial in cancer pain. While it involves oncology patients, human subjects, randomization, and a drug intervention, it does not present primary or secondary results. The primary efficacy endpoint is time to stable analgesia (not a time-to-event survival endpoint like OS/PFS). No Kaplan-Meier or HR data are reported.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Preoperative Radiotherapy and Postoperative Complications Among Patients with Primary Retroperitoneal Sarcoma: A Post Hoc Analysis of the EORTC-62092 (STRASS) Phase 3 Randomized Clinical Trial. PMID 41983724 · Ann Surg · 2026-Apr-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
FDA Approval Summary: Durvalumab for the Treatment of Adult Patients with Muscle-Invasive Bladder Cancer. PMID 41678313 · Clin Cancer Res · 2026-Apr-15 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 2 Figure · 2 Panel · risk unclear
A Multicenter Phase II Randomized Controlled Trial Comparing 177Lu-Dotatate/Capecitabine Combination Treatment with 177Lu-Dotatate Monotherapy in Patients with Neuroendocrine Tumors. PMID 41591997 · Clin Cancer Res · 2026-Apr-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Olopatadine plus mometasone for seasonal allergic rhinitis treatment: A pooled analysis of clinical trials. PMID 41985293 · Braz J Otorhinolaryngol · 2026-Apr-14 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
SENIPERA Phase 0/1 randomized window-of-opportunity clinical trial of SENIcapoc and PERAmpanel mono- and combination therapy of newly diagnosed glioblastoma: a trial protocol. PMID 41981510 · BMC Cancer · 2026-Apr-14 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
STRATEGIC-1: multiple-line, randomized, open-label GERCOR-PRODIGE-39 phase III trial in unresectable RAS/BRAF wild-type metastatic colorectal cancer. PMID 41980919 · Signal Transduct Target Ther · 2026-Apr-14 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 1 Figure · 2 Panel · risk unclear
Developing Transdiagnostic Single-Session Interventions for University Students Experiencing Disordered Eating: A Mixed-Method Co-Design Study. PMID 41978984 · Int J Eat Disord · 2026-Apr-14 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Dynamic Precision Oncology for Real-Time Molecular Monitoring and Management in Urothelial Carcinoma. PMID 42074119 · Int J Mol Sci · 2026-Apr-13 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
PARP Inhibitors and the Risk of Serum Creatinine Elevation in Ovarian Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PMID 42073552 · Cancers (Basel) · 2026-Apr-13 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Immunogenicity and Safety of a Full-Dose Regimen of Cell Culture-Derived Quadrivalent Inactivated Influenza Vaccine in Children Aged 6-35 Months: Results from a Multinational Phase 3 Randomised Controlled Trial. PMID 42042817 · Vaccines (Basel) · 2026-Apr-13 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Immunogenicity and safety of co-administration of adjuvanted respiratory syncytial virus prefusion F protein vaccine with 20-valent pneumococcal conjugate vaccine in adults aged ≥60 years: a randomized, non-inferiority trial. PMID 41994955 · Clin Infect Dis · 2026-Apr-13 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Impact of prevention of postoperative pulmonary complications with penehyclidine inhalation on long-term outcomes in high-risk patients: follow-up of a randomized trial. PMID 41973092 · J Anesth · 2026-Apr-13 The study is excluded because the drug intervention (penehyclidine) is not an oncology therapeutic agent; it is a perioperative supportive care measure aimed at preventing pulmonary complications, not treating the underlying malignancy.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Clinical value of intraoperative frozen section examination-assisted strategy in prostate biopsy: a comparative study of diagnostic efficiency and clinical practicality. PMID 41968340 · BMC Cancer · 2026-Apr-13 Study is a randomized, prospective, human oncology (prostate cancer) trial with original results. However, it is not a Phase III/IIIb or Phase II/III trial (phase not specified but appears to be a diagnostic study, not a definitive drug trial). It lacks a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.) or Kaplan-Meier/HR analysis. It evaluates a diagnostic procedure (biopsy strategy), not a drug-containing intervention.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Deutenzalutamide, a novel androgen receptor inhibitor, after progression on docetaxel and abiraterone in metastatic castration-resistant prostate cancer: results from the randomized phase III HC-1119-04 trial. PMID 41968137 · Signal Transduct Target Ther · 2026-Apr-13 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 2 Figure · 5 Panel · risk unclear
Comparative and Critical Analysis of Immune-based Combinations for First-line Treatment of Metastatic Renal Cell Carcinoma. PMID 42135107 · Clin Genitourin Cancer · 2026-Apr-12 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
[Effect of electroacupuncture on intestinal function after laparoscopic colorectal cancer surgery]. PMID 41987441 · Zhongguo Zhen Jiu · 2026-Apr-12 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
[Effects of electroacupuncture on gastrointestinal dysfunction and serum metabolites in postoperative patients with gastric cancer]. PMID 41987440 · Zhongguo Zhen Jiu · 2026-Apr-12 The study is an oncology RCT in humans but is ineligible because the intervention is non-drug (electroacupuncture) and it lacks a primary/key secondary time-to-event efficacy endpoint.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Newer Therapeutics to Selectively Kill Clostridioides difficile and Restore the Microbiome. PMID 42042323 · Infect Dis Rep · 2026-Apr-11 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
No major effect of age (< 40 vs. ≥ 40 years) on response to secukinumab in patients with axSpA: a post hoc analysis of six phase 3 trials. PMID 41965705 · Arthritis Res Ther · 2026-Apr-11 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Expiratory Muscle Strength Training in Head and Neck Cancer Survivors With Radiation-Associated Dysphagia: Results of a Pilot Prospective Trial. PMID 41964362 · Head Neck · 2026-Apr-11 The record describes a single-arm pilot study of a non-drug intervention (expiratory muscle strength training) in head and neck cancer survivors. It lacks randomization, a drug intervention, and a time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Annual immunogenicity measurements in randomized clinical trials help reveal heterogeneity in long-term vaccine efficacy: a pooled logistic regression modeling study. PMID 41793964 · Vaccine · 2026-Apr-11 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Adenovirus type 5 vector-based COVID-19 vaccine does not increase the likelihood of HIV infection. PMID 41785679 · Vaccine · 2026-Apr-11 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Upadacitinib monotherapy versus methotrexate monotherapy in methotrexate-naïve Japanese patients with rheumatoid arthritis: long-term efficacy and safety through 5 years in the SELECT-EARLY study. PMID 41967478 · Mod Rheumatol · 2026-Apr-10 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Phase 3 study results for oral PCSK9 inhibition with enlicitide. PMID 41966715 · Med · 2026-Apr-10 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Androgen receptor pathway inhibitor intensification in non-metastatic hormone-sensitive prostate cancer: current evidence and clinical implications. PMID 41963635 · Clin Transl Oncol · 2026-Apr-10 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Six-month efficacy and safety of oxymetazoline hydrochloride 0.1% in Japanese patients with acquired blepharoptosis: a phase 3 study. PMID 41961227 · Jpn J Ophthalmol · 2026-Apr-10 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Cardiac biomarkers in patients with renal cell carcinoma treated with immune checkpoint inhibitors. PMID 41912436 · Oncologist · 2026-Apr-10 The record is from a randomized Phase III oncology trial with a drug intervention, but the reported analysis focuses on cardiac biomarkers and safety, not a primary or key secondary time-to-event efficacy endpoint like OS or PFS.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -